These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 36494311)

  • 21. Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies.
    Au TH; Wang K; Stenehjem D; Garrido-Laguna I
    J Gastrointest Oncol; 2017 Jun; 8(3):387-404. PubMed ID: 28736627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report.
    Christofyllakis K; Monteiro AR; Cetin O; Kos IA; Greystoke A; Luciani A
    J Geriatr Oncol; 2022 Nov; 13(8):1071-1083. PubMed ID: 35525790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application of histology-agnostic treatments in metastatic colorectal cancer.
    Sartore-Bianchi A; Agostara AG; Patelli G; Mauri G; Pizzutilo EG; Siena S
    Dig Liver Dis; 2022 Oct; 54(10):1291-1303. PubMed ID: 35701319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FDA Approvals of Oncology Drugs for Tissue-Agnostic Indications.
    Zettler ME
    Target Oncol; 2023 Sep; 18(5):777-792. PubMed ID: 37477750
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Controversy of tissue-agnostic approvals in immunotherapy and targeted therapy.
    Bose CK
    Med Oncol; 2022 Apr; 39(5):67. PubMed ID: 35478274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer.
    Stein MK; Oluoha O; Patel K; VanderWalde A
    J Pers Med; 2021 Jun; 11(6):. PubMed ID: 34198738
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.
    Melosky B; Wheatley-Price P; Juergens RA; Sacher A; Leighl NB; Tsao MS; Cheema P; Snow S; Liu G; Card PB; Chu Q
    Lung Cancer; 2021 Oct; 160():136-151. PubMed ID: 34353680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutational analysis using next generation sequencing in pediatric thyroid cancer reveals BRAF and fusion oncogenes are common.
    Newfield RS; Jiang W; Sugganth DX; Hantash FM; Lee E; Newbury RO
    Int J Pediatr Otorhinolaryngol; 2022 Jun; 157():111121. PubMed ID: 35397361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions.
    Kim JH; Hong JH; Choi YL; Lee JA; Seo MK; Lee MS; An SB; Sung MJ; Cho NY; Kim SS; Shin YK; Kim S; Kang GH
    J Pathol; 2021 Dec; 255(4):399-411. PubMed ID: 34402529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.
    Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C
    Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M; Costa DB; Rangachari D
    Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
    Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm.
    Adashek JJ; Subbiah V; Kurzrock R
    Trends Cancer; 2021 Jan; 7(1):15-28. PubMed ID: 33008795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The application of target-based tissue-agnostic therapy in the treatment of lung cancer].
    Peták I
    Magy Onkol; 2020 Sep; 64(3):206-215. PubMed ID: 32966351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers.
    Boilève A; Verlingue L; Hollebecque A; Boige V; Ducreux M; Malka D
    Expert Opin Investig Drugs; 2021 Apr; 30(4):401-409. PubMed ID: 33641556
    [No Abstract]   [Full Text] [Related]  

  • 36. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.
    Chakravarty D; Johnson A; Sklar J; Lindeman NI; Moore K; Ganesan S; Lovly CM; Perlmutter J; Gray SW; Hwang J; Lieu C; André F; Azad N; Borad M; Tafe L; Messersmith H; Robson M; Meric-Bernstam F
    J Clin Oncol; 2022 Apr; 40(11):1231-1258. PubMed ID: 35175857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions.
    Yoshino T; Pentheroudakis G; Mishima S; Overman MJ; Yeh KH; Baba E; Naito Y; Calvo F; Saxena A; Chen LT; Takeda M; Cervantes A; Taniguchi H; Yoshida K; Kodera Y; Kitagawa Y; Tabernero J; Burris H; Douillard JY
    Ann Oncol; 2020 Jul; 31(7):861-872. PubMed ID: 32272210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The FDA Oncology Center of Excellence and precision medicine.
    Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
    Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted Therapies in Advanced Cholangiocarcinoma.
    Storandt MH; Kurniali PC; Mahipal A; Jin Z
    Life (Basel); 2023 Oct; 13(10):. PubMed ID: 37895447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of Microsatellite Instability Biomarkers via Next-Generation Sequencing.
    Bonneville R; Krook MA; Chen HZ; Smith A; Samorodnitsky E; Wing MR; Reeser JW; Roychowdhury S
    Methods Mol Biol; 2020; 2055():119-132. PubMed ID: 31502149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.